heptavalent pneumococcal conjugate vaccine (Prevnar)

Subscribe to Selected New Research on heptavalent pneumococcal conjugate vaccine

80 relevant articles (8 outcomes, 18 trials/studies) found for this Bio-Agent

Description: contains 7 pneumococcal serotypes (6B, 14, 19F, 23F, 18C, 4, 9V), each conjugated individually to the outer membrane protein complex of Neisseria meningitidis; designed for young children; Prevenar/Prevnar is tradename

Also Known As:

Prevnar; Prevenar; 7-valent PncOMPC vaccine; MnCC; Mnc-CRM197; PNCRM7; seven-valent pneumococcal PS-meningococcal OMPC conjugate vaccine

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 314

Biological Products

Vaccines: 15360

Bacterial Vaccines: 332

Meningococcal Vaccines: 103

heptavalent pneumococcal conjugate vaccine: 80

Streptococcal Vaccines: 8

Pneumococcal Vaccines: 319

heptavalent pneumococcal conjugate vaccine: 80

Experts

1.	Ray, Paula: 3 articles (09/2006 - 09/2002)
2.	Hansen, John: 3 articles (09/2006 - 09/2002)
3.	Lewis, Edwin: 3 articles (09/2006 - 09/2002)
4.	Principi, Nicola: 2 articles (01/2007 - 06/2003)
5.	Esposito, Susanna: 2 articles (01/2007 - 06/2003)
6.	Fireman, Bruce: 2 articles (09/2006 - 09/2002)
7.	Lee, Janelle: 2 articles (09/2006 - 09/2002)
8.	Black, Steven B: 2 articles (04/2006 - 09/2002)
9.	Varon, E: 1 article (06/2008)
10.	Lecuyer, A: 1 article (06/2008)

Related Diseases

1.	Otitis Media 09/01/2006 - "Persistence of this trend will produce a significant reduction of the otitis media burden and further enhance the cost-effectiveness of heptavalent pneumococcal conjugate vaccine." 01/01/2002 - "In addition, the US trial and another randomized, double-blind trial conducted in Finland, showed that PNCRM7 vaccine efficacy against all otitis media episodes was between 6 and 7%. " 11/01/2008 - "This study sought to determine the microbiology of recurrent acute otitis media (AOM) and AOM treatment failure (AOMTF) in the context of widespread use of heptavalent pneumococcal conjugate vaccine (PCV7). " 11/01/2007 - "The more widely documented shift in the causative pathogens of acute otitis media (AOM) following the release of the heptavalent pneumococcal conjugate vaccine (PCV7) has also been documented in two studies of ABS in children. " 04/01/2007 - "In this study we estimated the effect of routine childhood immunization with heptavalent pneumococcal conjugate vaccine on frequent otitis media (3 episodes in 6 months or 4 episodes in 1 year) and pressure-equalizing tube insertions. " Order ALL the reference details at left...
2.	Pneumonia (Pneumonitis) 11/01/2008 - "We describe the antimicrobial susceptibility and serotype distributions of Streptococcus pneumoniae causing bacteraemia and community-acquired pneumonia in these countries from 1999/2000 to 2006/7, predominantly prior to the introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) into the standard vaccination schedule in September 2006. " 09/01/2006 - "Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs." 06/20/2003 - "Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy." 09/01/2002 - "OBJECTIVE: To determine the effectiveness of the Wyeth heptavalent pneumococcal conjugate vaccine against clinical and radiograph-confirmed pneumonia in children. " 09/01/2002 - "Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia." Order ALL the reference details at left...
3.	Bacteremia 04/01/2003 - "Six (75%) of 8 cases of S pneumoniae bacteremia were caused by serotypes included in the current heptavalent pneumococcal conjugate vaccine, which was not available at the time of this study. " 08/01/2001 - "As indicated by the results of this study, the heptavalent pneumococcal conjugate vaccine may prevent the majority of occult pneumococcal bacteremia episodes. " 08/01/2001 - "This study was conducted to determine the serotype prevalence of Streptococcus pneumoniae isolates from children with occult bacteremia and to document the proportion that would be covered by the recently licensed heptavalent pneumococcal conjugate vaccine. " 08/01/2007 - "BACKGROUND: The introduction of vaccination with the heptavalent pneumococcal conjugate vaccine (PCV7) has produced an important decrease in the incidence of Streptococcus pneumoniae occult bacteremia (OB). " 08/01/2001 - "The high potential efficacy of the heptavalent pneumococcal conjugate vaccine for strains that cause occult bacteremia in our population may have a profound effect on the treatment of children with fever without a source. " Order ALL the reference details at left...
4.	Tetanus 03/01/2007 - "Vaccination resulted in a significant increase (P < or = .05) in antibody levels to each vaccine antigen studied, with 100% of patients achieving protection against tetanus (GMC, 2.2 IU/mL; 95% CI, 1.8-2.7 IU/mL), 100% achieving protection against Hib (GMC, 8.4 microg/mL; 95% CI, 7.6-9.3 microg/mL), 100% achieving protection against measles (GMC, 2435 mIU/mL; 95% CI, 1724-3439 mIU/mL), 100% achieving protection against meningococcus C (GMT, 1:5706; 95% CI, 1:3510-1:9272), 92% achieving protection against the 3 poliovirus serotypes, and > or = 80% achieving protection against each of the heptavalent pneumococcal conjugate vaccine-associated serotypes. " 01/01/2009 - "One study (120 children) found that when diphtheria-polio-tetanus-acellular pertussis-Haemophilus influenzae type b (DPTaP-Hib; Pentacel) and pneumococcus (Prevnar) were injected sequentially during the same office visit, observer- and parent-reported pain scores were lower when DPTaP-Hib was injected first (SMD, -0.40 and -0.57, respectively; P <or= 0.03). " 11/01/2008 - "STUDY DESIGN: A total of 484 healthy infants aged 6 to 12 weeks were randomly assigned to 1 of 2 groups to receive 3 doses of Pediarix (combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliovirus vaccine [DTaP-HBV-IPV]), Prevnar (7-valent pneumococcal conjugate vaccine [PCV7]), and ActHIB (Haemophilus influenzae type b conjugate vaccine [Hib]) at 2, 4, and 6 months of age with RIX4414 either coadministered at 2 and 4 months (Co-ad) or administered separately at 3 and 5 months (Sep-ad). " 11/01/2003 - "PARTICIPANTS: Infants receiving their 2-month immunizations, consisting of 4 injections (diphtheria and tetanus toxoids and acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae b conjugate and hepatitis B vaccine [Comvax], and heptavalent pneumococcal conjugate vaccine [Prevnar]). " Order ALL the reference details at left...
5.	Fever (Fevers) 07/01/2007 - "OBJECTIVE: To calculate the impact of the heptavalent pneumococcal conjugate vaccine (PCV-7) in the management of fever without source (FWS) in infants according to vaccination rates. " 08/01/2006 - "OBJECTIVE: To evaluate the impact of the introduction of the heptavalent pneumococcal conjugate vaccine (PCV-7) in the management of children aged 6 to 24 months with high fever without source (FWS) in a pediatric emergency department (PED). " 02/01/2001 - "Fever occurred in 23 to 37% of children, but the contribution of MnCC to the febrile reactions is unknown. " 04/01/1998 - "Mild to moderate postvaccination fever was common in both the PNCRM7 and control vaccine groups, however DTP/HbOC was administered concurrently. " 08/01/2001 - "The high potential efficacy of the heptavalent pneumococcal conjugate vaccine for strains that cause occult bacteremia in our population may have a profound effect on the treatment of children with fever without a source. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	heptavalent pneumococcal conjugate vaccine (Prevnar)
2.	Antigens
3.	Vaccines
4.	Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
5.	CRM197 (non-toxic variant of diphtheria toxin)
6.	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)
7.	Antibodies
8.	Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (ActHIB)
9.	Tetanus Toxoid (Vaccine, Tetanus)
10.	Carbon Monoxide

Related Therapies and Procedures

1.	Middle Ear Ventilation (Tympanostomy)
2.	Injections
3.	Antibiotic Prophylaxis

Best Treatments:
Research Summary Report
on Otitis Media

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 311 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>